Protara Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
23.1%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$1.39next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
TARA-002 Complete Response (CR) Rate in BCG-Unresponsive NMIBC (6 Months) Quarterly6,820.0%Target: Registrational cohort completion and BLA filing
Unrestricted Cash, Cash Equivalents, and Marketable Debt Securities Quarterly177.4MTarget: Sufficient to fund operations into 2028
TARA-002 Clinical Success Rate in Lymphatic Malformations (STARBORN-1) Quarterly10,000.0%Target: BLA submission in 2H 2027
Watch Items
- Enrollment completion of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trialTrigger: H2 2026Action: Initiate data analysis and prepare for regulatory discussions
- Initiation of the ADVANCED-3 registrational trial in BCG-Naïve NMIBC patientsTrigger: H2 2026Action: Open clinical sites and begin patient screening
- Interim dose-confirmation data from the THRIVE-3 registrational trial of IV Choline ChlorideTrigger: H2 2026Action: Review pharmacokinetic primary endpoints and confirm Phase 3 dosing
Research as of 20 Jun 2026